Drug Trial Radar · NCT04033445
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,064
Actual
Start
Sep 26, 2019
Primary completion
Sep 19, 2023
Study completion Jul 16, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).
Conditions
- Ulcerative Colitis
Interventions
PlaceboDrug
Participants will receive matching placebo IV or SC.
GuselkumabDrug
Participants will receive guselkumab IV or SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Induction Study 1: Percentage of Participants With Clinical Response at Week I-12Time frame: At Week I-12
- Induction Study 2: Percentage of Participants With Clinical Remission at Week I-12Time frame: At Week I-12
- Maintenance Study: Percentage of Participants With Clinical Remission at Week M-44Time frame: At Week M-44
Locations
392 sites in 34 countries. Site status is shown where the registry gives one.
Om Research LLC
Lancaster, California
UCLA
Los Angeles, California
Peak Gastroenterology Associates 1
Colorado Springs, Colorado
Florida Research Network, LLC
Gainesville, Florida
University of Florida Health Jacksonville
Gainesville, Florida
Harmony Medical Research Institute, Inc.
Hialeah, Florida
UF Health Jacksonville Gastroenterology Emerson
Jacksonville, Florida
I.H.S. Health. LLC
Kissimmee, Florida
Columbus Clinical Services LLC
Miami, Florida
Vista Health Research, LLC
Miami, Florida
Orlando Health
Orlando, Florida
Care Access Research, Orlando
Orlando, Florida
Synexus Clinical Research US Inc 2
Pinellas Park, Florida
Univ. of South Florida Med. Group
Tampa, Florida
Atlanta Gastroenterology Associates
Atlanta, Georgia
Morehouse School of Medicine
Atlanta, Georgia
The Emory Clinic
Atlanta, Georgia
Atlanta Gastroenterology Associates 1
Atlanta, Georgia
Atlanta Center For Gastroenterology
Decatur, Georgia
Gastroenterolgy Associates of Central GA
Macon, Georgia
University of Chicago
Chicago, Illinois
Health Science Research Center
Pratt, Kansas
Tri-State Gastroenterology Assoc
Crestview Hills, Kentucky
Baystate Medical Center
Springfield, Massachusetts
Clinical Research Institute of Michigan, LLC
Clinton Township, Michigan
Revive Research Institute
Farmington Hills, Michigan
Infusion Associates
Grand Rapids, Michigan
Mid-America Gastro-Intestinal Consultants
Kansas City, Missouri
Barnes-jewish Hospital
St Louis, Missouri
Las Vegas Medical Research
Las Vegas, Nevada
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Duke University Hospital Medical Center
Raleigh, North Carolina
Synexus Clinical Research US Inc
Columbus, Ohio
Digestive Specialists, Inc
Springboro, Ohio
Gastro Intestinal Research Institute of Northern Ohio LLC
Westlake, Ohio
Care Access Research, Poland
Youngstown, Ohio
Digestive Disease Specialists Inc
Oklahoma City, Oklahoma
US Digestive Health
Wyomissing, Pennsylvania
Synexus Clinical Research US Inc 1
Anderson, South Carolina
Gastroenterology Associates of Orangeburg, SC
Orangeburg, South Carolina
Showing 40 of 392 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.